Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Cancer Genomics Group, |
RCV001030682 | SCV001193510 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2019-05-01 | criteria provided, single submitter | research | |
Labcorp Genetics |
RCV001034932 | SCV001198235 | uncertain significance | Bloom syndrome | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with glycine at codon 240 of the BLM protein (p.Asp240Gly). The aspartic acid residue is weakly conserved and there is a moderate physicochemical difference between aspartic acid and glycine. This variant is present in population databases (rs757324067, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with BLM-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001034932 | SCV001456646 | uncertain significance | Bloom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |